loanranger asked, "Does it also make sense for IPIX shareholders?" Your question was in regard to the relationship between IPIX and BeaMedical Technologies, LTD and the likelihood that BeaMed's leading-edge, image guided surgical laser platform for treating previously inoperable cases of epilepsy, and enabling new treatment options for cancer cases in multiple key specialties, including early-stage lung cancer, and if IPIX investment in BeaMed makes sense for IPIX investors? (i.e.,will it be profitable?) The answer to your question is that when BeaMed's StingRay laser system goes commercial, it will be hugely profitable for IPIX investors as IPIX owns a big piece of BeaMedical Technologies, LTD.
I'm sure you know that there is never a guarantee of success when it comes to investing, but based on all the information available, IPIX's current ownership of a substantial piece of BeaMed represents an amazing opportunity. The information that follows is taken from Innovation Pharmaceuticals (IPIX) Press Releases on this subject.
"Following the closing under the Purchase Agreement in June, 2022, IPIX owns approximately 35.7% of BT BeaMedical Technologies, LTD (formerly known as Squalus Medical Ltd.) outstanding equity securities and approximately 41.6% of BeaMed's equity securities on a fully diluted basis."
IPIX investors and potential new investors can read about BeaMed's rapid advance of its new image guided surgical laser platform for treating previously inoperable cases of epilepsy and for enabling new treatment options for cancer cases in multiple specialties. Aside from the many exciting things going on with Brilacidin, I believe that being able to buy into BeaMed via IPIX for a couple of pennies per share is an amazing investment opportunity. If you have more questions about this subject, go to IPIX press releases and BeaMed's website to due your own due diligence. As to your question about reverse mergers, there is information available to you on that topic on the internet. Good luck.
Bullish
